Cargando…
Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies
BACKGROUND: Phosphodiesterase type 5 inhibitor (PE5i) administration may stimulate the proliferation and survival of melanocytes. However, discrepancies remain regarding the association between PDE5i use and melanoma risk in observational studies in humans. AIM: To evaluate the association between P...
Autores principales: | Han, Xinming, Han, Yan, Zheng, Yongsheng, Sun, Qiang, Ma, Tao, Dai, Li, Zhang, Junyi, Xu, Lianji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5804137/ https://www.ncbi.nlm.nih.gov/pubmed/29440918 http://dx.doi.org/10.2147/OTT.S142637 |
Ejemplares similares
-
Chaetocin induces apoptosis in human melanoma cells through the generation of reactive oxygen species and the intrinsic mitochondrial pathway, and exerts its anti-tumor activity in vivo
por: Han, Xinming, et al.
Publicado: (2017) -
Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: a meta-analysis and systematic review
por: Wang, Jie, et al.
Publicado: (2017) -
Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017) -
Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis
por: Feng, Shijian, et al.
Publicado: (2018) -
No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma
por: Wang, Jenny Z., et al.
Publicado: (2019)